# SynDevRx

Source: https://onco.cc/companies/syndevrx/  
OnCo record `syndevrx` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SynDevRx is a Massachusetts biotech whose polymer-drug conjugate evexomostat targets the metabolic side of cancer, blocking MetAP2 to counter the weight gain and insulin surge that undermine PI3K inhibitors and hormone therapy.

## Summary

SynDevRx develops evexomostat (SDX-7320), a polymer conjugate of a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor designed to avoid the neurotoxicity of earlier agents. MetAP2 inhibition reduces angiogenesis and improves insulin sensitivity, so the drug is being tested to prevent hyperglycaemia and weight gain in patients receiving alpelisib for PIK3CA-mutant breast cancer and in metabolically unhealthy patients with triple-negative breast cancer and prostate cancer.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: SynDevRx, Inc.
- Tags: drug-maker
- HQ: Cambridge, Massachusetts
- Type: biotech
- Website: https://www.syndevrx.com/

## Sources

- Official website: https://www.syndevrx.com/

## Connected records

- drugs: [Evexomostat](https://onco.cc/drugs/evexomostat/)

---
JSON: https://onco.cc/api/v1/entities/syndevrx.json